알엑스 온콜로지 홀딩스(ALXO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.70 (-2.30%), 시가총액 $0.27B, 52주 최저~최고 $0.41 ~ $2.60.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast ca
알엑스 온콜로지 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
알엑스 온콜로지 홀딩스의 현재 주가는 $1.70 (-2.30%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
알엑스 온콜로지 홀딩스의 시가총액은 약 $0.27B입니다.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD